This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients.
Xu F, Zhang L, He W, Song D, Ji X, Shao J…
Cancer Type: Liver
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis
This systematic review and meta-analysis of cohort studies of patients with cirrhosis aimed to evaluate the benefit and harms of HCC surveillance in patients with cirrhosis.
Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA…
Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer
The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer.
Huan L…
APASL 2023 Taiwan Congress Report
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease. …
Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models
A/Prof Simone Strasser recently published an independent commentary in the Australian Medical Research and Journal “Research Review”, covering at length topics such as non-alcoholic liver disease as an increasing risk factor, hepatocellular carcinoma surveillance including ultrasound as the current standard of care, the nature of patients who should undergo surveillance, serological biomarkers, and biopsy. Watch the interview with A/Prof Strasser on her thoughts about HCC in Australia….
